Equities analysts forecast that Perrigo Company PLC (NYSE:PRGO) will post $1.08 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Perrigo’s earnings. The lowest EPS estimate is $0.99 and the highest is $1.14. Perrigo reported earnings per share of $0.97 during the same quarter last year, which would indicate a positive year over year growth rate of 11.3%. The company is scheduled to announce its next earnings report before the market opens on Thursday, February 27th.
According to Zacks, analysts expect that Perrigo will report full-year earnings of $4.02 per share for the current fiscal year, with EPS estimates ranging from $3.86 to $4.10. For the next fiscal year, analysts forecast that the company will post earnings of $4.42 per share, with EPS estimates ranging from $4.19 to $4.82. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Perrigo.
A number of analysts have issued reports on PRGO shares. ValuEngine lowered shares of Perrigo from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 29th. Cantor Fitzgerald boosted their price target on shares of Perrigo from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $55.80.
NYSE:PRGO traded down $0.25 on Friday, reaching $57.71. 782,633 shares of the company’s stock were exchanged, compared to its average volume of 997,165. The company has a quick ratio of 1.32, a current ratio of 2.07 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $8.23 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 6.81 and a beta of 1.43. The business has a fifty day moving average of $55.74 and a 200-day moving average of $52.66. Perrigo has a 52-week low of $40.68 and a 52-week high of $60.98.
In other Perrigo news, VP Todd W. Kingma sold 2,300 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $54.91, for a total transaction of $126,293.00. Following the sale, the vice president now directly owns 31,184 shares in the company, valued at $1,712,313.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in PRGO. Parallel Advisors LLC boosted its holdings in Perrigo by 343.3% in the third quarter. Parallel Advisors LLC now owns 931 shares of the company’s stock valued at $52,000 after purchasing an additional 721 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co boosted its holdings in Perrigo by 13.5% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,685 shares of the company’s stock valued at $87,000 after purchasing an additional 200 shares in the last quarter. Vestcor Investment Management Corp acquired a new position in Perrigo in the fourth quarter valued at approximately $122,000. Tower Research Capital LLC TRC boosted its holdings in Perrigo by 7.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,167 shares of the company’s stock valued at $163,000 after purchasing an additional 207 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in Perrigo in the third quarter valued at approximately $165,000. 86.33% of the stock is owned by institutional investors and hedge funds.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Read More: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.